Sanofi
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Large accelerated filer
State of Incorporation France
Business Address 46 AVENUE DE LA GRANDE ARMEE, PARIS, I0, 75017
Mailing Address 46 AVENUE DE LA GRANDE ARMEE, PARIS, I0, 75017
Phone 33153774400
Fiscal Year End 1231
EIN 133529324
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | March 24, 2026 | View on SEC |
| 6-K Foreign company current report | March 10, 2026 | View on SEC |
| 6-K Foreign company current report | March 4, 2026 | View on SEC |
| 6-K Foreign company current report | March 3, 2026 | View on SEC |
| 6-K Foreign company current report | February 23, 2026 | View on SEC |
| 20-F Foreign company annual report | February 17, 2026 | View on SEC |
| 6-K Foreign company current report | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 6-K Foreign company current report | February 12, 2026 | View on SEC |
Annual Reports
20-F February 17, 2026
- Sanofi reported strong financial performance with total revenue of €47.1 billion (+5.5%) and net income of €8.1 billion (+12%), primarily fueled by its Specialty Care portfolio and Dupixent.
- The company aggressively expanded its pipeline and market presence through strategic acquisitions (e.g., Provention Bio, Vigil Neuroscience, Blueprint Medicines) and key collaborations.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.